This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Saint Louis University. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations of Jonathan Oliva in the Field of FSHD Treatment
Introduction
Jonathan Oliva is an accomplished inventor based in Manchester, MO (US). He has made significant contributions to the field of medical research, particularly in the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD). His innovative work focuses on the modulation of DUX4 expression, which is crucial for developing effective therapies for this condition.
Latest Patents
Jonathan Oliva holds a patent for "BET inhibitors for modulating DUX4 expression in FSHD." This patent provides a detailed disclosure of BET inhibitors and their pharmaceutical compositions. The methods outlined in the patent involve administering a bromo- and extra-terminal (BET) domain inhibitor to treat patients with FSHD, thereby modulating DUX4 expression. This innovative approach has the potential to improve treatment outcomes for patients suffering from this debilitating disease.
Career Highlights
Jonathan Oliva is affiliated with Saint Louis University, where he conducts his research and develops his inventions. His work has garnered attention for its potential to change the landscape of FSHD treatment. With a focus on therapeutic agents that can be used alongside palliative treatments, Oliva's contributions are paving the way for new possibilities in patient care.
Collaborations
Jonathan collaborates with Francis M Sverdrup, a fellow researcher who shares his commitment to advancing the understanding and treatment of FSHD. Their partnership exemplifies the collaborative spirit of innovation in the medical research community.
Conclusion
Jonathan Oliva's innovative work in developing BET inhibitors represents a significant advancement in the treatment of FSHD. His contributions to medical research highlight the importance of innovation in addressing complex health challenges.